AbbVie Inc. (ABBV) Holdings Reduced by Broderick Brian C
Broderick Brian C cut its position in AbbVie Inc. (NYSE:ABBV) by 5.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,560 shares of the company’s stock after selling 1,550 shares during the period. Broderick Brian C’s holdings in AbbVie were worth $1,861,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. First Command Financial Services Inc. raised its stake in shares of AbbVie by 6.8% in the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock worth $102,000 after acquiring an additional 99 shares during the last quarter. Atwood & Palmer Inc. raised its stake in shares of AbbVie by 1,333.3% in the first quarter. Atwood & Palmer Inc. now owns 2,150 shares of the company’s stock worth $140,000 after acquiring an additional 2,000 shares during the last quarter. Tradewinds Capital Management LLC raised its stake in shares of AbbVie by 87.2% in the first quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company’s stock worth $148,000 after acquiring an additional 1,057 shares during the last quarter. American National Bank raised its stake in shares of AbbVie by 13.8% in the first quarter. American National Bank now owns 2,471 shares of the company’s stock worth $161,000 after acquiring an additional 299 shares during the last quarter. Finally, Signature Estate & Investment Advisors LLC bought a new position in shares of AbbVie in the first quarter worth about $183,000. Hedge funds and other institutional investors own 68.29% of the company’s stock.
In other AbbVie news, Chairman Richard A. Gonzalez sold 193,131 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the completion of the transaction, the chairman now owns 469,623 shares in the company, valued at approximately $33,343,233. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard A. Gonzalez sold 65,861 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $71.00, for a total transaction of $4,676,131.00. Following the transaction, the chief executive officer now owns 342,353 shares of the company’s stock, valued at approximately $24,307,063. The disclosure for this sale can be found here. In the last quarter, insiders sold 490,491 shares of company stock valued at $34,684,639. 0.23% of the stock is owned by company insiders.
A number of equities analysts have weighed in on ABBV shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $94.00 target price (up from $92.00) on shares of AbbVie in a research note on Monday, July 17th. Vetr downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $71.84 target price for the company. in a research note on Monday, May 15th. Societe Generale raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $85.00 target price on shares of AbbVie in a research note on Thursday, August 3rd. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $79.25.
AbbVie Inc. (NYSE ABBV) traded up 0.5389% during midday trading on Tuesday, hitting $87.4688. 4,643,542 shares of the company were exchanged. The firm’s 50-day moving average price is $72.68 and its 200-day moving average price is $68.66. AbbVie Inc. has a one year low of $55.06 and a one year high of $87.97. The stock has a market capitalization of $139.43 billion, a PE ratio of 21.5122 and a beta of 1.48.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. The business had revenue of $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the business earned $1.26 EPS. Equities research analysts anticipate that AbbVie Inc. will post $5.52 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a $0.64 dividend. The ex-dividend date is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a yield of 2.94%. AbbVie’s dividend payout ratio (DPR) is presently 62.90%.
ILLEGAL ACTIVITY WARNING: “AbbVie Inc. (ABBV) Holdings Reduced by Broderick Brian C” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/12/abbvie-inc-abbv-holdings-reduced-by-broderick-brian-c.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.